XBIO (Xenetic Biosciences) Cyclically Adjusted FCF per Share: $-29.67 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBIO Xenetic Biosciences Inc XBIO
78 GF Score
Price $2.48
GF Value $4.23
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Cyclically Adjusted FCF per Share?

Xenetic Biosciences XBIO 78 Cyclically Adjusted FCF per Share is $-29.67 as of Mar. 2026. GuruFocus rates XBIO with a GF Score™ of 78/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xenetic Biosciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.234. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-29.67 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 27.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Xenetic Biosciences was 27.50% per year. The lowest was 15.30% per year. And the median was 21.40% per year.

As of today (2026-07-30), Xenetic Biosciences's current stock price is $2.48. Xenetic Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-29.67. Xenetic Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Xenetic Biosciences  (NAS:XBIO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xenetic Biosciences Cyclically Adjusted FCF per Share Related Terms


Xenetic Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences Cyclically Adjusted FCF per Share Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -89.81 -93.08 -101.13 -54.61 -35.50

Xenetic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.52 -47.20 -39.95 -35.50 -29.67

XBIO vs ADIL, PULM, KAPA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Xenetic Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Cyclically Adjusted Price-to-FCF falls into.


XBIO
78GF Score
Xenetic Biosciences Inc XBIO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xenetic Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.234/330.2130*330.2130
=-0.234

Current CPI (Mar. 2026) = 330.2130.

Xenetic Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -20.908 241.018 -28.646
201609 -13.720 241.428 -18.766
201612 -67.014 241.432 -91.657
201703 3.887 243.801 5.265
201706 -27.288 244.955 -36.786
201709 -22.425 246.819 -30.002
201712 66.274 246.524 88.772
201803 -22.836 249.554 -30.217
201806 -28.603 251.989 -37.482
201809 -21.385 252.439 -27.974
201812 -13.346 251.233 -17.542
201903 -15.494 254.202 -20.127
201906 -11.943 256.143 -15.397
201909 -6.259 256.759 -8.050
201912 -2.764 256.974 -3.552
202003 -1.607 258.115 -2.056
202006 -2.068 257.797 -2.649
202009 -1.606 260.280 -2.038
202012 -1.413 260.474 -1.791
202103 -1.736 264.877 -2.164
202106 -0.831 271.696 -1.010
202109 -1.017 274.310 -1.224
202112 -1.085 278.802 -1.285
202203 -1.554 287.504 -1.785
202206 -0.518 296.311 -0.577
202209 -0.753 296.808 -0.838
202212 -0.499 296.797 -0.555
202303 -0.726 301.836 -0.794
202306 -0.832 305.109 -0.900
202309 -0.620 307.789 -0.665
202312 -0.515 306.746 -0.554
202403 -0.752 312.332 -0.795
202406 -0.341 314.175 -0.358
202409 -0.298 315.301 -0.312
202412 -0.437 315.605 -0.457
202503 -0.650 319.799 -0.671
202506 -0.249 322.561 -0.255
202509 -0.427 324.800 -0.434
202512 -0.111 324.054 -0.113
202603 -0.234 330.213 -0.234

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-29.67 mean?
Xenetic Biosciences (XBIO) has a Cyclically Adjusted FCF per Share of $-29.67 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Cyclically Adjusted FCF per Share too high?
Xenetic Biosciences' current Cyclically Adjusted FCF per Share is $-29.67. Overall, Xenetic Biosciences has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Cyclically Adjusted FCF per Share compare to ADIL and PULM?
Xenetic Biosciences' Cyclically Adjusted FCF per Share of $-29.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Cyclically Adjusted FCF per Share is $-29.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $2.48 — trading 41.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-29.67. Xenetic Biosciences' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Cyclically Adjusted FCF per Share is $-29.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.48 is trading 41.4% below its estimated GF Value™ of $4.23. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

  • Cyclically Adjusted FCF per Share: $-29.67
  • GF Value™: $4.23 vs. price of $2.48 (41.4% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
78GF Score

Get the complete analysis for XBIO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.48
Price
$4.23
GF Value